Table. Pivotal Trials Supporting Accelerated Approvals and Regulatory Outcomes of Oncology Accelerated Approval Drug-Indication Pairs, 2013 to 2017.

	No. (%)
	All indications (n = 46)	Original indications (n = 24)	Supplemental indications (n = 22)
Pivotal trial efficacy outcomes
Response rate	19 (41)	9 (38)	10 (45)
Response rate plus duration of response	21 (46)	11 (46)	10 (45)
Progression-free survival	4 (9)	2 (8)	2 (9)
Overall survival	1 (2)	1 (4)	0
Complete remission rate	1 (2)	1 (4)	0
Regulatory outcome
Converted to regular approval	29 (63)	14 (58)	15 (68)
Ongoing	7 (15)	4 (17)	3 (14)
Withdrawn	10 (22)	6 (25)	4 (18)
Time to conversion, median (IQR), d	972 (680-1274)
Time to withdrawal, median (IQR), d	1923 (1449-2517)